Download PDF

1. Company Snapshot

1.a. Company Description

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery.It operates in two segments, Codman Specialty Surgical and Tissue Technologies.The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.


It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices.In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair.Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products.


The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally.Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Show Full description

1.b. Last Insights on IART

Integra LifeSciences Holdings Corporation faced negative drivers, including reduced stakes from significant investors, such as Assenagon Asset Management S.A. (62% decrease) and Access Investment Management LLC (14.6% decrease). Additionally, the company received a "Reduce" rating from brokerages, with three analysts rating the stock as a sell. Despite beating Q4 earnings and revenue estimates, the company experienced margin pressure and a sales dip. Integra LifeSciences also reported a decrease in EPS compared to the previous year ($0.83 vs $0.97). (Source: MarketBeat, Zacks Consensus Estimate)

1.c. Company Highlights

2. Integra LifeSciences Delivers Mixed Results, Outlines 2026 Priorities

Integra LifeScies reported fourth-quarter 2025 revenue of $435 million, representing a decrease of 1.7% on a reported basis and an organic decline of 2.5%. However, the company saw a $33 million sequential increase in revenue from the third quarter due to improved supply and seasonality. Adjusted earnings per share (EPS) for the quarter was $0.83, beating estimates of $0.79. For the full year 2025, revenue was $1.635 billion, representing 1.5% growth on a reported basis and a 0.7% organic decline. The company delivered double-digit growth in several key products, including CereLink, MAYFIELD Capital, and DuraSorb programmable valves.

Publication Date: Mar -01

📋 Highlights
  • 2025 Full-Year Revenue: $1.635 billion, 1.5% reported growth but 0.7% organic decline.
  • Q4 Revenue and Adjusted EPS: $435 million revenue (1.7% reported decline, 2.5% organic), $0.83 adjusted EPS vs $0.97 prior year.
  • 2026 Revenue Guidance: $1.66 billion to $1.7 billion, indicating modest top-line growth expectations.
  • 2026 Cash Flow Outlook: Operating cash flow >$200 million (>$150 million improvement over 2025), driven by EU MDR savings and reduced CapEx.

Operational Highlights

Integra LifeSciences made significant operational progress in 2025, strengthening its quality management system, advancing its compliance master plan, and progressing execution of its risk-based remediation plan. The company also improved supply reliability, enhanced its execution capabilities, and delivered significant outcomes in key supply chain resiliency efforts. As Mojdeh Poul, President and Chief Executive Officer, noted, the company is focused on delivering best-in-class quality, driving supply chain reliability, accelerating growth, and igniting innovation in 2026.

2026 Guidance

Integra LifeSciences expects revenues to be in the range of $375 million to $390 million in the first quarter of 2026, representing reported growth of minus 2% to positive 1.9%. For the full year, the company expects revenues to be in the range of $1.66 billion to $1.7 billion, reflecting modest top-line growth expectations. Adjusted EPS is expected to be $0.37 to $0.45 in the first quarter and $2.30 to $2.40 for the full year. Analysts estimate revenue growth of 3.4% for 2026, slightly higher than the company's guidance.

Valuation

Integra LifeSciences trades at a P/E Ratio of -1.69, P/B Ratio of 0.84, and P/S Ratio of 0.54. The company's EV/EBITDA is -2.38, indicating that the market is pricing in significant challenges. However, with the company's focus on improving supply chain reliability and accelerating growth, there is potential for upside. The company's ROE is -44.49%, and ROIC is -14.14%, indicating that the company is still facing significant challenges in terms of profitability.

Cash Flow

Integra LifeSciences reported negative free cash flow of $5 million in the fourth quarter, driven by timing of collections and restructuring costs. However, the company expects a much-improved cash flow profile in 2026, with operating cash flow expected to be north of $200 million, a $150 million improvement over 2025. This is driven by reduced cash outlays from EU MDR compliance and Braintree, improved working capital profile, lower CapEx, and better EBITDA.

3. NewsRoom

Card image cap

Integra Q4 Earnings & Revenues Beat Estimates, Margins Down, Stock Up

Mar -02

Source: zacks.com

Card image cap

Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

Card image cap

Integra (IART) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Feb -26

Source: zacks.com

Card image cap

Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates

Feb -26

Source: zacks.com

Card image cap

Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb -26

Source: globenewswire.com

Card image cap

Integra LifeSciences Announces Key Executive Leadership Appointments

Feb -17

Source: globenewswire.com

Card image cap

Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026

Feb -09

Source: globenewswire.com

Card image cap

Brokerages Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Target Price at $15.00

Feb -08

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.96%)

6. Segments

Codman Specialty Surgical

Expected Growth: 4.8%

Growing demand for minimally invasive surgeries, increasing prevalence of neurological disorders, and advancements in surgical technologies are driving the growth of the neurosurgery and orthopedic surgery markets, benefiting Codman Specialty Surgical.

Tissue Technologies

Expected Growth: 8.5%

Growing demand for tissue repair and regeneration, increasing adoption of biomaterials, and advancements in bioactive molecules drive the growth of Tissue Technologies from Integra LifeSciences Holdings Corporation.

7. Detailed Products

Neuro Critical Care

Integra's Neuro Critical Care products are designed to help clinicians manage patients with severe head or spinal cord injuries, and those who require intensive care.

Orthopedics and Tissue Technologies

Integra's Orthopedics and Tissue Technologies products are used in orthopedic and reconstructive surgeries, and for the repair and replacement of damaged or diseased tissues.

Specialty Surgical Solutions

Integra's Specialty Surgical Solutions products are used in a variety of surgical procedures, including neurosurgery, orthopedic surgery, and general surgery.

Wound Reconstruction

Integra's Wound Reconstruction products are used to treat complex wounds, including those that are chronic, acute, or traumatic.

Dermal Sciences

Integra's Dermal Sciences products are used to treat a range of skin conditions, including wounds, burns, and skin defects.

OrthoEsthetics

Integra's OrthoEsthetics products are used in orthopedic and reconstructive surgeries to improve the aesthetic appearance of the skin.

8. Integra LifeSciences Holdings Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Integra LifeSciences Holdings Corporation is moderate due to the presence of alternative medical devices and technologies that can replace or complement the company's products.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Integra's products, which are often critical to medical procedures, giving the company an upper hand in pricing and negotiations.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of multiple suppliers for raw materials and components, but the company's dependence on a few critical suppliers for certain components.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the medical device industry, including regulatory hurdles, high research and development costs, and the need for specialized expertise.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of established competitors in the medical device industry, leading to intense competition for market share and pricing pressure.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 48.82%
Debt Cost 5.11%
Equity Weight 51.18%
Equity Cost 9.82%
WACC 7.52%
Leverage 95.40%

11. Quality Control: Integra LifeSciences Holdings Corporation passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Insulet

A-Score: 5.3/10

Value: 0.2

Growth: 9.6

Quality: 7.9

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
CONMED

A-Score: 4.8/10

Value: 7.4

Growth: 6.4

Quality: 5.9

Yield: 3.0

Momentum: 1.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Inari Medical

A-Score: 4.8/10

Value: 4.0

Growth: 8.0

Quality: 4.8

Yield: 0.0

Momentum: 9.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Bio-Rad

A-Score: 4.0/10

Value: 6.5

Growth: 2.3

Quality: 4.7

Yield: 0.0

Momentum: 5.0

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Inspire Medical Systems

A-Score: 3.2/10

Value: 1.1

Growth: 9.4

Quality: 6.9

Yield: 0.0

Momentum: 0.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Integra LifeSciences

A-Score: 3.0/10

Value: 8.3

Growth: 2.3

Quality: 4.1

Yield: 0.0

Momentum: 0.5

Volatility: 3.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.55$

Current Price

9.55$

Potential

-0.00%

Expected Cash-Flows